Paper Details

  1. Home
  2. Paper Details

Evaluation of the therapeutic potential of a CNP analog in a Fgfr3 mouse model recapitulating achondroplasia.

Author: BellSean M, Benoist-LasselinCatherine, BullensSherry, BuntingStuart, Di RoccoFederico, KaciNabil, Legeai-MalletLaurence, LorgetFlorence, MugnieryEmilie, MunnichArnold, O'NeillCharles A, OppeneerTodd, PengJeff, TsurudaLaurie S, WendtDan J

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Achondroplasia (ACH), the most common form of dwarfism, is caused by a genetic mutation. CNP, a naturally occurring protein, can block the effects of this mutation. This study tested a modified form of CNP (BMN 111) in mice with ACH. Treatment with BMN 111 resulted in improved bone growth, suggesting that it may be a promising treatment option for people with ACH.
Paper Details　
Original Abstract of the Article :
Achondroplasia (ACH), the most common form of dwarfism, is an inherited autosomal-dominant chondrodysplasia caused by a gain-of-function mutation in fibroblast-growth-factor-receptor 3 (FGFR3). C-type natriuretic peptide (CNP) antagonizes FGFR3 downstream signaling by inhibiting the pathway of mitog...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3516592/

データ提供：米国国立医学図書館（NLM）

Achondroplasia: Seeking a Solution in the Desert of Bone Growth

Imagine a vast desert landscape where a lone oasis, representing the growth plate, is stunted and underdeveloped. This is the reality for individuals with achondroplasia (ACH), a genetic disorder characterized by dwarfism. This study investigates the potential of a CNP analog, a naturally occurring substance involved in bone growth, as a treatment option for ACH. The study examines the effects of this analog in a mouse model of ACH, offering hope for a new therapeutic approach to this challenging condition.

A Potential Oasis for Growth: CNP Analog Shows Promise for ACH

This study showcases the promising potential of a CNP analog as a treatment option for ACH. The positive results in a mouse model of ACH offer a glimmer of hope for developing a new therapy for this challenging condition.

Navigating the Desert of Bone Growth Disorders: Seeking Expert Care

Bone growth disorders require specialized care and management. It is essential to consult an endocrinologist, orthopedic surgeon, or other qualified healthcare professionals for accurate diagnosis, individualized treatment plans, and ongoing support.

Dr.Camel's Conclusion

This study sheds light on a potential oasis in the desert of bone growth disorders, showcasing the promising potential of a CNP analog as a treatment option for achondroplasia. This research holds the potential to transform the lives of individuals with this condition, offering a glimmer of hope for achieving normal growth and development.

Date :
  1. Date Completed 2013-02-14
  2. Date Revised 2021-12-24
Further Info :

Pubmed ID

23200862

DOI: Digital Object Identifier

PMC3516592

Related Literature

Article Analysis
・Effects of vosoritide
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.